Skip to content
Dosage GuideResearch Reference

Adrenomedullin Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for Adrenomedullin. All information is for educational purposes only.

Quick Answer

Adrenomedullin is primarily administered intravenously in research settings. Clinical trials for sepsis have used continuous infusions of 5-50 ng/kg/min, requiring close blood pressure monitoring. MR-proADM, a more stable fragment, is measured in blood tests to assess cardiovascular risk. There are no established oral or subcutaneous dosing guidelines.

→ Adrenomedullin Benefits→ Adrenomedullin Side Effects→ Full Adrenomedullin Profile
Table of Contents

Standard Dosage Range

Research dosing range: 5-50 ng/kg/min (IV infusion); MR-proADM <0.75 nmol/L (low risk)

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Septic Shock (investigational)

5-50 ng/kg/minContinuous IV infusion
Duration

Variable (days)

Used in AdrenOSS-2 trial with Adrecizumab. Requires intensive care monitoring. Goal is endothelial stabilization.

Acute Heart Failure (investigational)

5-20 ng/kg/minContinuous IV infusion
Duration

Variable (days)

To reduce pulmonary vascular resistance and improve cardiac output. Blood pressure and heart rate monitoring essential.

Diagnostic Risk Stratification

N/ASingle measurement
Duration

N/A

MR-proADM blood test to assess risk in sepsis, pneumonia, and heart failure. Guide treatment decisions.

Timing & Frequency

Intravenous adrenomedullin is administered continuously in critical care settings. MR-proADM blood tests are performed as clinically indicated to assess cardiovascular risk and guide treatment.

Cycle Guidance

Continuous infusions are typically short-term (days) in acute settings. Long-term use is not established. MR-proADM monitoring can be repeated as needed for ongoing risk assessment.

Reconstitution Reference

Quick reference for reconstituting Adrenomedullin. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeN/A (typically supplied as a solution for IV infusion)
BAC Water VolumeN/A
Concentration & DrawVariable based on infusion rate
StorageFollow manufacturer instructions for IV solution storage
StabilityFollow manufacturer instructions for IV solution stability
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the typical dosage of adrenomedullin?
In research settings, adrenomedullin is administered intravenously as a continuous infusion at rates of 5-50 ng/kg/min. The dosage is tailored to the individual and closely monitored by medical professionals, especially in cases of septic shock or acute heart failure.
What is MR-proADM and how is it used?
MR-proADM, or mid-regional pro-adrenomedullin, is a stable surrogate for measuring adrenomedullin levels in the blood. It is used as a prognostic biomarker in sepsis, pneumonia, and heart failure. Elevated levels indicate a higher risk of adverse outcomes.
How is adrenomedullin administered?
Adrenomedullin is administered intravenously as a continuous infusion. This method allows for precise control over the dosage and ensures a consistent level of the peptide in the bloodstream.
Is there an oral form of adrenomedullin?
No, there is no commercially available oral form of adrenomedullin. It is primarily used intravenously in clinical research settings.

References

  1. 1
    Adrecizumab (anti-adrenomedullin antibody) in sepsis: AdrenOSS-2 trial results(2020)PubMed ↗
  2. 2
    Mid-regional pro-adrenomedullin as a prognostic biomarker in sepsis: systematic review(2014)PubMed ↗
  3. 3
    Adrenomedullin in cardiovascular disease: from bench to bedside(2005)PubMed ↗

Last updated: 2026-02-19